doksorubicin teva 2 mg/ml koncentrat za raztopino za infundiranje
teva pharma b.v. - doksorubicin - koncentrat za raztopino za infundiranje - doksorubicin 1,88 mg / 1 ml - doksorubicin
doksorubicin agila specialties 2 mg/ml koncentrat za raztopino za infundiranje
agila specialties uk limited - doksorubicin - koncentrat za raztopino za infundiranje - doksorubicin 1,88 mg / 1 ml - doksorubicin
doksorubicin agila specialties 2 mg/ml koncentrat za raztopino za infundiranje
agila specialties uk limited - doksorubicin - koncentrat za raztopino za infundiranje - doksorubicin 1,88 mg / 1 ml - doksorubicin
doksorubicin agila specialties 2 mg/ml koncentrat za raztopino za infundiranje
agila specialties uk limited - doksorubicin - koncentrat za raztopino za infundiranje - doksorubicin 1,88 mg / 1 ml - doksorubicin
doksorubicin agila specialties 2 mg/ml prašek za koncentrat za raztopino za
agila specialties uk limited - doksorubicin - prašek za koncentrat za raztopino za infundiranje - doksorubicin 1,88 mg / 1 ml - doksorubicin
doksorubicin agila specialties 2 mg/ml prašek za koncentrat za raztopino za
agila specialties uk limited - doksorubicin - prašek za koncentrat za raztopino za infundiranje - doksorubicin 1,88 mg / 1 ml - doksorubicin
doksorubicin agila specialties 2 mg/ml koncentrat za raztopino za infundiranje
agila specialties uk limited - doksorubicin - koncentrat za raztopino za infundiranje - doksorubicin 1,88 mg / 1 ml - doksorubicin
medicinski kisik istrabenz plini 100 % medicinski plin, kriogenski
istrabenz plini d.o.o. - kisik - medicinski plin, kriogenski - kisik 100 % / 1 vsebnik - kisik
medicinski kisik istrabenz plini 100 % medicinski plin, kriogenski
istrabenz plini d.o.o. - kisik - medicinski plin, kriogenski - kisik 100 % / 1 vsebnik - kisik
adcetris
takeda pharma a/s - brentuximab vedotin - lymphoma, non-hodgkin; hodgkin disease - antineoplastična sredstva - hodgkin lymphomaadcetris is indicated for adult patients with previously untreated cd30+ stage iv hodgkin lymphoma (hl) in combination with doxorubicin, vinblastine and dacarbazine (avd). adcetris is indicated for the treatment of adult patients with cd30+ hl at increased risk of relapse or progression following autologous stem cell transplant (asct). adcetris is indicated for the treatment of adult patients with relapsed or refractory cd30+ hodgkin lymphoma (hl):following asct, orfollowing at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option. systemic anaplastic large cell lymphomaadcetris in combination with cyclophosphamide, doxorubicin and prednisone (chp) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (salcl). adcetris is indicated for the treatment of adult patients with relapsed or refractory salcl. cutaneous t cell lymphomaadcetris is indicated for the treatment of adult patients with cd30+ cutaneous t cell lymphoma (ctcl) after at least 1 prior systemic therapy.